Canada Pension Plan Investment Board lifted its position in shares of Astrazeneca PLC (NYSE:AZN) by 148,401.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 148,501 shares of the company’s stock after buying an additional 148,401 shares during the quarter. Canada Pension Plan Investment Board’s holdings in Astrazeneca PLC were worth $5,031,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Intl Fcstone Inc. increased its position in shares of Astrazeneca PLC by 146.9% during the second quarter. Intl Fcstone Inc. now owns 32,549 shares of the company’s stock worth $1,110,000 after buying an additional 19,365 shares during the period. Royal Bank of Canada increased its position in shares of Astrazeneca PLC by 12.2% during the second quarter. Royal Bank of Canada now owns 1,855,405 shares of the company’s stock worth $63,250,000 after buying an additional 201,885 shares during the period. Assetmark Inc. boosted its stake in Astrazeneca PLC by 9.0% during the second quarter. Assetmark Inc. now owns 208,714 shares of the company’s stock worth $7,115,000 after acquiring an additional 17,306 shares in the last quarter. Blair William & Co. IL boosted its stake in Astrazeneca PLC by 62.3% during the second quarter. Blair William & Co. IL now owns 42,117 shares of the company’s stock worth $1,436,000 after acquiring an additional 16,174 shares in the last quarter. Finally, Buckingham Capital Management Inc. bought a new position in Astrazeneca PLC during the second quarter worth $792,000. Institutional investors own 14.16% of the company’s stock.
Shares of Astrazeneca PLC (NYSE:AZN) opened at $33.25 on Wednesday. The company has a market cap of $83,324.70, a PE ratio of 7.85, a PEG ratio of 2.84 and a beta of 0.75. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.32 earnings per share. sell-side analysts expect that Astrazeneca PLC will post 1.93 EPS for the current year.
WARNING: “Astrazeneca PLC (AZN) Stake Raised by Canada Pension Plan Investment Board” was originally posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://weekherald.com/2017/11/15/astrazeneca-plc-azn-stake-raised-by-canada-pension-plan-investment-board.html.
Several research analysts recently issued reports on the stock. Citigroup Inc. raised shares of Astrazeneca PLC to a “buy” rating in a research note on Wednesday, October 18th. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. BMO Capital Markets set a $38.00 target price on shares of Astrazeneca PLC and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Finally, Cowen and Company reissued a “hold” rating and set a $34.00 target price on shares of Astrazeneca PLC in a research note on Friday, July 28th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $34.20.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.